ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Evaluating the Role of Thrombin in Saphenous Vein Graft Failure After Heart Bypass Surgery

This study is currently recruiting participants.
Verified by National Heart, Lung, and Blood Institute (NHLBI), December 2007

Sponsors and Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
University of Maryland
Information provided by: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT00481806
  Purpose

Heart bypass surgery, also known as coronary artery bypass graft (CABG) surgery, creates a detour around the blocked part of a heart artery to restore blood supply to the heart muscle. The saphenous vein, located along the inside of the leg, is commonly used to create the bypass in a CABG surgery. An abnormal increase in the blood clotting protein thrombin may cause the saphenous vein graft to close up and eventually fail. This study will evaluate the relationship between thrombin levels and saphenous vein graft failures in people undergoing a CABG procedure.


Condition
Coronary Artery Bypass
Thrombosis

MedlinePlus related topics:   Coronary Artery Bypass Surgery   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Case-Only, Prospective
Official Title:   Thrombin Dysregulation Leads to Early Saphenous Vein Graft Failure

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Primary Outcome Measures:
  • Amplifying the severity of all three risk factors of Virchow's triad is expected to lead to a synergistic increase in regional thrombin formation [ Time Frame: Measured at 5 years ] [ Designated as safety issue: Yes ]
  • Pressure distention is the main stimulus that creates a loss of thrombin control within the SVG [ Time Frame: Measured at 5 years ] [ Designated as safety issue: Yes ]
  • Accurate tests of graft quality will be developed that provide rapid results for ready translation into clinical applications [ Time Frame: Measured at 5 years ] [ Designated as safety issue: Yes ]
  • Aprotinin or bivalirudin will effectively suppress thrombin generation and its effects within the highest risk grafts [ Time Frame: Measured at 5 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

Whole blood and vein samples


Estimated Enrollment:   410
Study Start Date:   February 2007
Estimated Study Completion Date:   December 2011

Detailed Description:

The saphenous vein, which runs from the ankle to the groin along the inside of the leg, is commonly used as a graft for people undergoing a CABG surgery. The vein is removed from the leg and reattached to the heart to create a detour around the blocked part of a coronary artery. Following this procedure, many people are prescribed aspirin as a way to increase the chance that the graft procedure will be successful. However, saphenous vein graft failure may still occur in some people, indicating a need to understand why this happens and who might be at risk for graft failure. Thrombin, a protein involved in the blood clotting process, is somehow related to aspirin resistance, abnormalities in blood flow, and cell disruption within the saphenous vein, all factors thought to increase the risk of graft failure. The purpose of this study is to evaluate the likelihood that a burst in thrombin contributes to graft failure in people who have recently undergone a CABG procedure using the saphenous vein.

This study will enroll individuals undergoing CABG surgery at the University of Maryland. Prior to and immediately following surgery, an incision will be made in the skin and the time required for the blood to form a clot will be determined. During surgery, participants' blood vessels will be examined using imaging and cell analysis techniques. Blood collection will occur before surgery, immediately after surgery, and on Days 1, 3, and 30 following surgery. A portion of blood will be frozen for future analysis. An x-ray of the saphenous vein will be performed on Day 5 and again at a follow-up visit 6 to 12 months following surgery. Kidney function will be measured at both of these visits prior to the x-ray procedure. At the second visit, health and mental status questionnaires will be completed.

  Eligibility
Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample

Study Population

Male and female patients between the the age of 18-90 years belonging to all races will be enrolled in the study


Criteria

Inclusion Criteria:

  • Scheduled for CABG surgery at University of Maryland Medical System (UMMS)
  • For females, willing to use a reliable form of birth control for the duration of the study

Exclusion Criteria:

  • Non-dermatologic allergy to intravenous (IV) radiographic contrast
  • Creatinine levels greater than 2.0 mg/dL
  • Pregnant
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00481806

Contacts
Contact: Robert S. Poston, MD     410-328-5842 ext 8469     rposton@smail.umaryland.edu    

Locations
United States, Maryland
University of Maryland School of Medicine     Recruiting
      Baltimore, Maryland, United States, 21201
      Principal Investigator: Robert S. Poston, MD            

Sponsors and Collaborators

Investigators
Principal Investigator:     Robert S. Poston, MD     University of Maryland    
  More Information


Responsible Party:   University of Maryland Medical Center ( Dr. Robert Poston, MD / Associate Professor of Surgery )
Study ID Numbers:   479, R01 HL084080-01A1
First Received:   May 31, 2007
Last Updated:   December 17, 2007
ClinicalTrials.gov Identifier:   NCT00481806
Health Authority:   United States: Federal Government

Keywords provided by National Heart, Lung, and Blood Institute (NHLBI):
Virchow's Triad  
Thrombin  
Graft Failure  

Study placed in the following topic categories:
Thrombin
Embolism and Thrombosis
Embolism
Vascular Diseases
Thrombosis

Additional relevant MeSH terms:
Coagulants
Therapeutic Uses
Hematologic Agents
Cardiovascular Diseases
Pharmacologic Actions
Hemostatics

ClinicalTrials.gov processed this record on October 03, 2008




Links to all studies - primarily for crawlers